Ventripoint Diagnostics Ltd. (FRA:5V7)

Market Cap	13.31M +30.0%
Revenue (ttm)	107.46K +28.6%
Net Income	-2.48M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0615
Previous Close	0.0620
Day's Range	0.0615 - 0.0615
52-Week Range	0.0390 - 0.1220
Beta	n/a
RSI	47.61
Earnings Date	Apr 30, 2026

About Ventripoint Diagnostics

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, in...

• Industry: Electromedical and Electrotherapeutic Apparatus
• CEO: Hugh MacNaught
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5V7

Financial Performance

In 2024, Ventripoint Diagnostics's revenue was 95,172, an increase of 93.51% compared to the previous year's 49,183. Losses were -4.92 million, 0.98% more than in 2023.

Financial numbers in CAD